Promising Results for enVVeno Medical in the Treatment of Venous Insufficiency

enVVeno Medical Corporation (NASDAQ: NVNO), an innovator in the treatment of venous diseases, has announced that the primary efficacy data from its pivotal VenoValve trial in the United States will be presented at the annual American Venous Forum congress in Tampa, Florida, on March 6, 2024. Dr. Cassius Iyad Ochoa Chaar, from the Yale School of Medicine, will share these data, highlighting the improvement in the clinical condition of subjects, assessed by the revised venous clinical severity score (rVCSS).

The rVCSS, a globally used assessment system, has shown a significant improvement in this study in patients suffering from Severe Chronic Venous Insufficiency (CVI), thus establishing the potential of the VenoValve. An improvement of at least three points in the rVCSS is considered by the FDA as a clinically significant benefit, a threshold reached for a significant portion of the patients in the SAVVE study, all of whom had previously failed conventional treatments.

Chronic Venous Insufficiency, caused by failure of the venous valves, severely impairs daily functions and can lead to venous ulcers. enVVeno Medical is addressing this unmet need with its flagship product, the VenoValve®, a major innovation aiming to surgically replace defective venous valves.

enVVeno Medical's VenoValve® represents a significant breakthrough, offering new hope for patients affected by severe CVI. This development is particularly relevant as the medical community seeks sustainable solutions for venous diseases, affecting millions of people each year in the United States.